Rankings
▼
Calendar
HRTX
Heron Therapeutics, Inc.
$162M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$33M
+4.4% YoY
Gross Profit
$23M
71.2% margin
Operating Income
-$4M
-13.6% margin
Net Income
-$5M
-14.8% margin
EPS (Diluted)
$-0.03
QoQ Revenue Growth
-8.9%
Cash Flow
Operating Cash Flow
$3M
Free Cash Flow
$3M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$221M
Total Liabilities
$261M
Stockholders' Equity
-$40M
Cash & Equivalents
$26M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$33M
$31M
+4.4%
Gross Profit
$23M
$13M
+76.6%
Operating Income
-$4M
-$25M
+82.1%
Net Income
-$5M
-$25M
+80.6%
Revenue Segments
C I N V A N T I
$23M
72%
Z Y N R E L E F
$6M
20%
S U S T O L
$3M
9%
← FY 2024
All Quarters
Q4 2024 →
HRTX Q3 2024 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena